loading
Schlusskurs vom Vortag:
$1.55
Offen:
$1.58
24-Stunden-Volumen:
348.21K
Relative Volume:
0.79
Marktkapitalisierung:
$90.55M
Einnahmen:
$21.05M
Nettoeinkommen (Verlust:
$-89.22M
KGV:
-0.8939
EPS:
-1.79
Netto-Cashflow:
$-64.50M
1W Leistung:
+0.00%
1M Leistung:
+25.98%
6M Leistung:
-67.68%
1J Leistung:
-81.50%
1-Tages-Spanne:
Value
$1.56
$1.6499
1-Wochen-Bereich:
Value
$1.48
$1.65
52-Wochen-Spanne:
Value
$1.02
$9.69

Tscan Therapeutics Inc Stock (TCRX) Company Profile

Name
Firmenname
Tscan Therapeutics Inc
Name
Telefon
857-399-9500
Name
Adresse
880 WINTER STREET, WALTHAM
Name
Mitarbeiter
195
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-05
Name
Neueste SEC-Einreichungen
Name
TCRX's Discussions on Twitter

Vergleichen Sie TCRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TCRX
Tscan Therapeutics Inc
1.60 90.55M 21.05M -89.22M -64.50M -1.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-05-16 Eingeleitet BTIG Research Buy
2024-05-13 Eingeleitet Needham Buy
2023-06-22 Eingeleitet Wedbush Outperform

Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten

pulisher
Apr 30, 2025

BlackRock, Inc. Reduces Stake in TScan Therapeutics Inc by 43.05% - GuruFocus

Apr 30, 2025
pulisher
Apr 29, 2025

Geode Capital Management LLC Has $2.93 Million Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting - Nasdaq

Apr 28, 2025
pulisher
Apr 28, 2025

TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

TScan Unveils Groundbreaking CD45-Targeted Cell Therapy Research at Major ASGCT Conference - Stock Titan

Apr 28, 2025
pulisher
Apr 22, 2025

What is the investor’s view on Tscan Therapeutics Inc (TCRX)? - uspostnews.com

Apr 22, 2025
pulisher
Apr 17, 2025

Investing in Tscan Therapeutics Inc (TCRX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com

Apr 17, 2025
pulisher
Apr 12, 2025

Prudential Financial Inc. Acquires Shares of 10,415 TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average PT from Brokerages - Defense World

Apr 11, 2025
pulisher
Apr 09, 2025

TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com

Apr 08, 2025
pulisher
Apr 08, 2025

Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts - Benzinga

Apr 08, 2025
pulisher
Apr 01, 2025

Monitoring Gentherm Inc (THRM) after recent insider movements - knoxdaily.com

Apr 01, 2025
pulisher
Apr 01, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 31, 2025
pulisher
Mar 28, 2025

Tscan Therapeutics Inc [TCRX] Shares Fall Approximately -81.72% Over the Year - Knox Daily

Mar 28, 2025
pulisher
Mar 27, 2025

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - Quantisnow

Mar 27, 2025
pulisher
Mar 27, 2025

Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan

Mar 27, 2025
pulisher
Mar 17, 2025

TScan Therapeutics’ (TCRX) Overweight Rating Reiterated at Morgan Stanley - The AM Reporter

Mar 17, 2025
pulisher
Mar 17, 2025

Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

TScan Therapeutics (NASDAQ:TCRX) Earns Overweight Rating from Morgan Stanley - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

Weekly Investment Analysts’ Ratings Changes for TScan Therapeutics (TCRX) - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 13, 2025

HC Wainwright Expects Weaker Earnings for TScan Therapeutics - MarketBeat

Mar 13, 2025
pulisher
Mar 12, 2025

Positive Buy Rating for TScan Therapeutics Driven by Promising Clinical Data and Strong Financial Position - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Head to Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Novavax (NASDAQ:NVAX) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Analysts Set Expectations for TCRX FY2029 Earnings - MarketBeat

Mar 11, 2025
pulisher
Mar 11, 2025

TScan Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Q2 EPS Estimate for TScan Therapeutics Lowered by Analyst - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Wedbush Equities Analysts Cut Earnings Estimates for TCRX - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Research Analysts Set Expectations for TCRX FY2029 Earnings - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Barclays Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

TScan Therapeutics’ (TCRX) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 (NASDAQ:TCRX) - Seeking Alpha

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Reiterates "Buy" Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat

Mar 07, 2025
pulisher
Mar 07, 2025

TScan Therapeutics price target lowered to $3 from $14 at Barclays - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Needham & Company LLC Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

TScan Therapeutics (NASDAQ:TCRX) Earns Outperform Rating from Wedbush - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

H.C. Wainwright maintains $15 target on Tscan shares By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.

Mar 06, 2025
pulisher
Mar 06, 2025

H.C. Wainwright maintains $15 target on Tscan shares - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Breaking Down TScan Therapeutics: 4 Analysts Share Their Views - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire

Mar 06, 2025
pulisher
Mar 05, 2025

TScan Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million -March 05, 2025 at 04:54 pm EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Tscan Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

TScan Therapeutics reports Q4 EPS (30c), consensus (28c) - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 05, 2025
pulisher
Mar 05, 2025

TScan Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 05, 2025

Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Tscan Therapeutics Inc-Aktie (TCRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lynx1 Capital Management LP
10% Owner
Dec 12 '24
Buy
3.01
31,800
95,629
5,257,347
Lynx1 Capital Management LP
10% Owner
Nov 15 '24
Buy
4.34
947
4,114
5,225,547
Klencke Barbara
Director
Sep 23 '24
Buy
5.29
5,000
26,450
45,000
Klencke Barbara
Director
Aug 23 '24
Buy
5.69
5,000
28,450
35,000
Klencke Barbara
Director
Aug 26 '24
Buy
5.53
5,000
27,650
40,000
ZDRAVESKI ZORAN
See Remarks
Aug 23 '24
Option Exercise
3.38
157,186
531,520
169,402
ZDRAVESKI ZORAN
See Remarks
Aug 23 '24
Sale
5.78
164,686
952,116
4,716
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Kapitalisierung:     |  Volumen (24h):